Novartis AG - ADR
-2.48 %
3.18 %
Yet to be announced
Company Overview
Novartis AG researches, develops, manufactures, and markets healthcare products. The company operates through two segments, Innovative Medicines and Sandoz. Sandoz provides finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals.
Revenue Sources
PassBased on review of Novartis's business operations and revenue sources, the company's primary income comes from the development and sale of pharmaceutical products and healthcare solutions. These activities are considered halal as they provide beneficial medical treatments and contribute to human health and wellbeing.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $12.51b | $8.83b | - | $246.0m | 0.00% | 2.79% |
| March 31, 2024 | $11.83b | $8.42b | $6.0m | $221.0m | 0.05% | 2.62% |
| Dec. 31, 2023 | $11.78b | $9.41b | - | $217.0m | 0.00% | 2.31% |
| Sept. 30, 2023 | $12.09b | $10.55b | $225.0m | $222.0m | 1.86% | 2.10% |
Analysis of the last four quarters shows that interest expense as a percentage of total expenses has remained consistently low. The interest expense ratios were well below the 5% threshold that would indicate significant reliance on interest-based financing.
The interest income has also been minimal relative to total revenue, indicating that earning interest is not a significant part of the company's business model.
Operational Ethics
PassWhile Novartis maintains operations in various countries worldwide, our research has not identified any material ongoing associations with entities involved in human rights violations. The company's global operations appear to be conducted with appropriate oversight and compliance with international standards.
Comments